Evidence map›Paper›PMID 31616320›Full record

ArticleFrontiers in physiology2019

Anti-inflammatory and Regulatory Effects of Huanglian Jiedu Decoction on Lipid Homeostasis and the TLR4/MyD88 Signaling Pathway in LPS-Induced Zebrafish.

Junyi Zhou, Xinru Gu, Xiaorui Fan, Yanyan Zhou, Hongjie Wang, Nan Si, Jian Yang, Baolin Bian, Haiyu Zhao

Open access · goldAbstract read
In one paragraph

Article in Frontiers in physiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. The signal pathways and treatment of cytokine storm in COVID-19.Signal transduction and targeted therapy · 2021
    Review
  5. Article
  6. Huanglian Jiedu Decoction Exerts Antipyretic Effect by Inhibiting MAPK Signaling Pathway.Evidence-based complementary and alternative medicine : eCAM · 2021
    Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Junyi ZhouInstitute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.
Xinru GuInstitute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.
Xiaorui FanInstitute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.
Yanyan ZhouInstitute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.
Hongjie WangInstitute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.
Nan SiInstitute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.
Jian YangInstitute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.
Baolin BianInstitute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.
Haiyu ZhaoInstitute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.
Chinese Academy of Medical Sciences & Peking Union Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Huanglian Jiedu decoction (HLJDD) has been used in the clinical treatment of inflammatory conditions. To clarify the mechanism of its comprehensive anti-inflammatory activities, the correlation between lipid homeostasis and the TLR4/MyD88 signaling pathway in zebrafish was established in the present study. In the lipopolysaccharide (LPS)-induced inflammation in zebrafish model, RT-PCR assays of five inflammatory cytokines and six targeted proteins were measured. Lipidomics analysis was conducted to identify potential lipid markers. HLJDD displayed strong efficacies, with a 61% anti-inflammatory rate at a concentration of 50 μg/mL. The activation of TLR4/MyD88 played an essential role in the inflammatory process. All protein indexes in the HLJDD group exhibited a tendency to reverse back to normal levels. Moreover, 79 potential pathological lipid biomarkers were identified. Compared with the model group, 61 therapeutic lipid biomarkers were detected in HLJDD group. Most perturbations of lipids were ameliorated by HLJDD, mainly through the glycerophospholipid metabolic pathway. In the visual network study, the corresponding lipoproteins such as PLA

Indexed as

anti-inflammatory activityHuanglian Jiedu decoctionlipidomic profilelipopolysaccharideTLR4/MyD88 signaling pathwayzebrafish

Identifiers

PMID31616320
PMCPMC6775191
OpenAlexW2975417207

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.